kabutan

Nxera Pharma Co., Ltd.(4565) Summary

4565
TSE Prime
Nxera Pharma Co., Ltd.
973
JPY
+22
(+2.31%)
Apr 28, 3:30 pm JST
6.11
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
1.44
Yield
ー%
Margin Trading Ratio
456.65
Stock Price
Apr 28, 2026
Opening Apr 28, 9:03 am
973 JPY 6.10 USD
Previous Close Apr 27
951 JPY 5.96 USD
High Apr 28, 9:03 am
977 JPY 6.13 USD
Low Apr 28, 9:04 am
954 JPY 5.98 USD
Volume
557,100
Trading Value
0.54B JPY 3.39M USD
VWAP
967.77 JPY 6.08 USD
Minimum Trading Value
97,300 JPY 611 USD
Market Cap
0.09T JPY 0.55B USD
Number of Trades
894
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
High
1-Year Average
1,294
1-Year High Apr 1, 2026
10,109
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 176,800 5,933,400 33.56
Apr 17, 2026 168,700 5,752,300 34.10
Apr 10, 2026 192,000 5,655,600 29.46
Apr 3, 2026 213,300 5,673,800 26.60
Mar 27, 2026 169,000 5,401,300 31.96
Company Profile
Nxera Pharma Co., Ltd. is a drug discovery venture specializing in the development of drugs targeting membrane protein GPCRs in areas such as neurology, immunology, and gastroenterology.
Sector
Pharmaceuticals
Nxera Pharma Co., Ltd. is a biopharmaceutical company with a core focus on a drug discovery platform targeting GPCRs (G protein-coupled receptors), handling everything from research and development to sales of pharmaceuticals. The company is actively pursuing a growth strategy through acquisitions. Its UK subsidiary is responsible for drug discovery, translational medicine, preclinical and early clinical development. Clinical development and sales in Japan and Korea are managed by a wholly-owned subsidiary based in Japan and a subsidiary based in Korea, respectively. The company also envisions future business expansion into the APAC (Asia-Pacific) region. Nxera Pharma's strengths lie in GPCR structural analysis using StaR technology, early-stage lead compound generation, and candidate exploration. The company has established a global drug discovery network.